WATCH ON-DEMAND 👆

From AI to Impact: How GPT Applications are Accelerating Drug Discovery

In this session, we explored how GPT applications can streamline complex research processes, enhance data-driven decision-making, and expedite the journey from drug discovery to market.

Key topics included:

  • An overview of GPT technology and its applications in drug discovery research.
  • The benefits of harnessing GPT applications for drug discovery, including increased efficiency, reduced costs, and accelerated innovation.
  • Addressing the challenges of AI adoption, with AI hallucinations, inconsistent answers, and the long tail issue.
  • A glimpse into the future of drug discovery research, as shaped by AI and GPT applications, such as conversational interfaces with Knowledge Graphs. 
webinar-lp-form-icon-white

Watch On-Demand Now

Fill out the form below to access the recorded session


Meet Your Hosts

yiannis-bio

Co-founder & CEO
Yiannis is the Co-Founder & CEO of Causaly, a leading AI life sciences company. With extensive experience in AI technologies, he has helped transform research organizations for some of the world's top Biopharma companies. Prior to founding Causaly, Yiannis worked as a consultant for over a decade, advising global corporations across a wide range of industries. He holds an MBA from Hong Kong University of Science and Technology, and a BSc/MSc in Computer Science.

Artur_headshot-300x300

Co-founder & CTO
Artur is the Co-Founder & CTO of Causaly, a leading AI life sciences company. With a background in computer science, machine learning, and bioinformatics, he has architected the core AI technologies since the company's foundation in 2018. Before Causaly, Artur worked for 7 years in academia on machine learning applications for vision and language problems in Robotics. He holds a Master's degree in computer science from the University of Edinburgh and a Bachelor's degree from the University of Dublin.